Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer

Our study aimed to evaluate the efficacy and resistance mechanisms of first-line epidermal growth factor receptor (EGFR) inhibitor therapy in patients with advanced non –small-cell lung cancer (NSCLC) harbouring uncommon EGFR exon 19 deletion-insertion (19delins) variants.

Source: European Journal of Cancer - November 7, 2020 Category: Cancer & Oncology Authors: Xingzhou Peng, Xiaoyan Long, Li Liu, Liang Zeng, Haiyan Yang, Wenjuan Jiang, Dehua Liao, Kunyan Li, Jing Wang, Analyn Lizaso, Xinru Mao, Qinqin Xu, Aaron S. Mansfield, Nong Yang, Yongchang Zhang Tags: Original Research Source Type: research